CSIMarket Company Name, Ticker, Customers, else..
 
Orchard Therapeutics Plc  (NASDAQ: ORTX)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 23
 Employees 100
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) 1

Business Description


Orchard Therapeutics Plc is a biotechnology company specializing in the development of gene therapies for rare diseases. They focus on using ex-vivo autologous hematopoietic stem cell gene therapy to provide potentially curative treatments for patients with severe genetic disorders. Orchard Therapeutics aims to deliver transformative gene therapies that address the underlying cause of the disease and provide long-term benefits for patients. They have a pipeline of programs targeting various inherited disorders, including rare diseases affecting the immune system, blood disorders, metabolic disorders, and neurometabolic disorders. The company is headquartered in London, United Kingdom, and was founded in 2015.


   Company Address: 245 Hammersmith Road London 0
   Company Phone Number: (0) 203 808-8286   Stock Exchange / Ticker: NASDAQ ORTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DNA        0.44% 
GILD   -0.27%    
IMCR   -0.79%    
PSTX   -0.79%    
RGNX        17.94% 
SGEN        4.77% 
• View Complete Report
   



Product Service News

Orchard Therapeutics: Unleashing the Game-changer - HSC Gene Therapy's Versatility in Tackling Neurometabolic Diseases at ASGCT 2024.

Published Tue, May 7 2024 11:01 AM UTC

These presentations underpinned the tremendous scope and variety of HSC gene therapy a pioneering and innovative treatment that is shaking the foundations of our perspective on the management of challenging medical conditions.Orchard s presentations brought a spotlight on the potential capabilities and broad utility of HSC gene therapy. Notably, this therapeutic approach e...
Announcement

Orchard Therapeutics' CEO Dr. Bobby Gaspar: A Global Pioneer in Health Innovation Named in the 2024 TIME100 Health List.

Published Fri, May 3 2024 11:01 AM UTC

In a testament to his monumental impact and revolutionary advancements in the global health sector, Dr. Bobby Gaspar, co-founder and Chief Executive Officer (CEO) of Orchard Therapeutics, has been named to the inaugural TIME100 Health list for 2024. The list, compiled annually, recognizes the ingenuity, innovation, and tangible influence of the most revolutionary individuals...
Clinical Study

Revolutionary Gene Therapy for Early-onset Metachromatic Leukodystrophy Launches in the U.S., Offering Hope and Convenience for Affected Families

Published Wed, Mar 20 2024 11:00 AM UTC

Orchard Therapeutics, a global gene therapy company, recently announced its plans for the U.S. launch of Lenmeldy (atidarsagene autotemcel), the first and only approved therapy for children with Early-onset Metachromatic Leukodystrophy (EO-MLD). This groundbreaking treatment aims to transform the lives of patients suffering from this rare and devastating genetic disorder.Met...
Management Announcement

Orchard Therapeutics: Pioneering Breakthrough Treatment while Navigating Financial Waters

Published Mon, Mar 18 2024 7:41 PM UTC

Orchard Therapeutics: Breakthrough Treatment for Metachromatic Leukodystrophy and Financial Challenges
In a groundbreaking development, Orchard Therapeutics has received FDA approval for its therapy, Lenmeldy (atidarsagene autotemcel), making it the sole treatment available for eligible children with Early-onset Metachromatic Leukodystrophy (MLD) in the United States. Th...
Product Service News

Orchard Therapeutics Embarks on Ground-breaking Gene Therapy Trial for MPS-I Hurler Syndrome with OTL-203 Trial Launch

Published Mon, Feb 5 2024 12:00 PM UTC

Orchard Therapeutics, a leading global gene therapy company, has recently announced the randomization of the first patient in a registrational trial of its experimental gene therapy OTL-203 as a treatment for Mucopolysacianosis Type I (MPS-I) Hurler Syndrome. The therapy, which is based on an innovative ex vivo autologous hematopoietic stem cell gene therapy approach, aims ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.44
Working Capital Ratio 0.9
Leverage Ratio (MRQ) 1.7
Total Debt to Equity 0.45
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.04 $
Revenues (TTM) 0.96 $
Cash Flow (TTM) -
Cash 1.03 $
Book Value 3.51 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 218,390
Net Income per Employee (TTM) -729,210
Receivable Turnover Ratio (TTM) 3.61
Inventory Turnover Ratio (TTM) 1.2
Asset Turnover Ratio (TTM) 0.15

Profitability Ratios Current
Gross Margin (MRQ) 72.31 %
Operating Margin (MRQ) -342.83 %
Net Margin (MRQ) -560.44 %
Net Cash Flow Margin (MRQ) -234.91 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.